Ophelia
-
Study: More OUD Patients Stay in Treatment When Offered Buprenorphine via Telemedicine
Patients with opioid use disorder are more likely to stick with their treatment plan when offered buprenorphine via telemedicine, according to a new study. The study involved 1,378 patients, and their 180-day treatment retention rate was 56.4%.
-
‘The Stakes Couldn’t Be Higher’: How DEA’s Proposal Will Affect Telehealth Controlled Substance Prescribing
The DEA recently released proposed rules that would require an in-person visit before a patient can receive a telehealth prescription for a controlled substance. The DEA touts the change as a way to ensure patient safety, but several telehealth advocates argue it will greatly disrupt access for those who need the drugs — especially at a time when the mental health and substance use crisis is growing.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Empire BCBS adds 4 virtual behavioral health companies to its provider network
The four companies are Alma, Headway, NOCD and Ophelia. Alma and Headway will help Empire expand its mental health provider network, while NOCD and Ophelia will address specific conditions: obsessive-compulsive disorder and opioid use disorder, respectively.
-
Why decentralization & digitization could be the key to unlock the future of addiction care
A significant obstacle to patients battling opioid addiction is that most treatment programs require frequent in-person visits to medical centers. But many addiction care specialists think decentralizing programs from medical centers could help patients stay on track.